Shares of JBM HEALTHCARE (02161) experienced a sharp decline, dropping more than 12%. At the time of writing, the stock was down 12.28%, trading at HK$2.00 with a turnover of HK$4.1982 million.

The sell-off followed the release of the company's full-year results for the period ending March 31, 2026. The company reported revenue of approximately HK$835 million, representing a year-on-year increase of about 6.7%. Profit attributable to equity holders was around HK$201 million, marking a growth of approximately 1.9% compared to the previous year.

Earnings per share came in at 24.63 HK cents, with a proposed final dividend of 7.35 HK cents per share.

According to the company's announcement, the revenue growth was primarily driven by strong performance in the branded pharmaceuticals and branded traditional Chinese medicine segments. However, this positive contribution was partially offset by weaker performance in the health supplements division.